Immunology and efficacy of MF59-adjuvanted vaccines

Immunology and efficacy of MF59-adjuvanted vaccines

Adjuvants are included in vaccine formulations to enhance the immunogenicity and efficacy of vaccines. MF59® is an oil-in-water emulsion adjuvant and licensed for use in pandemic and seasonal influenza vaccines in many countries. MF59 is safe and well tolerated in humans. MF59-adjuvanted vaccination...

Full description

Bibliographic Details
Main Authors:	Eun-Ju Ko, Sang-Moo Kang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	mf59 influenza adjuvant immune mechanisms cd4-independent
Online Access:	http://dx.doi.org/10.1080/21645515.2018.1495301

Similar Items

Development of MF-59 adjuvant using chitosan derivatives to influenza vaccine
by: Alireza Loghmani, et al.
Published: (2020-06-01)

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico
by: Aurelio Cruz-Valdez, et al.
Published: (2018-02-01)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
by: Michele A. Kohli, et al.
Published: (2022-08-01)

Formulation of hepatitis B vaccine in MF59 adjuvant and comparison of its immunization with Iran\'s commercial hepatitis B vaccine
by: Reyhaneh Mirzaei, et al.
Published: (2018-10-01)

Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults
by: Eve Versage, et al.
Published: (2021-12-01)

Comparative Study on the Efficacy of MF 59, ISA70 VG, and Nano-Aluminum Hydroxide Adjuvants, Alone and with Nano-Selenium on Humoral Immunity Induced by a Bivalent Newcastle+Avian Influenza Vaccine in Chickens
by: M Radmehri, et al.
Published: (2021-11-01)

Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
by: Mallory L. Myers, et al.
Published: (2022-09-01)

Vaccine adjuvants – understanding molecular mechanisms to improve vaccines
by: Adrian Egli, et al.
Published: (2014-05-01)

Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus
by: Mallory L. Myers, et al.
Published: (2023-09-01)

A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis
by: Tamara Aghebati, et al.
Published: (2016-12-01)

Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity
by: Zhuofan Li, et al.
Published: (2021-01-01)

Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence
by: Ilaria Loperto, et al.
Published: (2019-05-01)

Adjuvanted influenza vaccines
by: John S. Tregoning, et al.
Published: (2018-03-01)

Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications
by: Constantina Boikos, et al.
Published: (2021-08-01)

Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway
by: Eui Ho Kim, et al.
Published: (2020-06-01)

MF59 Promoted the Combination of CpG ODN1826 and MUC1-MBP Vaccine-Induced Antitumor Activity Involved in the Enhancement of DC Maturation by Prolonging the Local Retention Time of Antigen and Down-Regulating of IL-6/STAT3
by: Jing Jie, et al.
Published: (2022-09-01)

PPD in HBsAg vaccine formulation suppressed IFN-γ and IL-4 cytokine responses and induced long-lived humoral immune responses: Results from 220-day monitoring of specific IgG responses
by: Rayhaneh Mirzaee, et al.
Published: (2022-11-01)

Cost-Effectiveness of Vaccination of Older Adults with an MF59<sup>®</sup>-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
by: Jorge Jacob, et al.
Published: (2023-03-01)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
by: Airi Poder, et al.
Published: (2023-09-01)

Sign Retention in Classical MF-DFA
by: Mengdie Yang, et al.
Published: (2022-06-01)

Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM) – protocol for prospective cohort study
by: D. Bogdanet, et al.
Published: (2020-07-01)

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant
by: Naru Zhang, et al.
Published: (2022-02-01)

A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria
by: Abdülkerim Yıldız, et al.
Published: (2014-08-01)

Flublok Quadrivalent Vaccine Adjuvanted with R-DOTAP Elicits a Robust and Multifunctional CD4 T Cell Response That Is of Greater Magnitude and Functional Diversity Than Conventional Adjuvant Systems
by: Chantelle L. White, et al.
Published: (2024-03-01)

Effects of Smoothing and Adaptive Filtering in Multifocal Electroretinography (mfERG)
by: Christopher Patrick Long, et al.
Published: (2023-08-01)

A Splice Site Mutation Associated with Congenital CD59 Deficiency
by: Jiani N. Chai, et al.
Published: (2022-05-01)

O papel das proteínas reguladoras do complemento CD55/CD59 em células de sangue periférico de pacientes com lúpus eritematoso sistêmico The role of CD55/CD59 complement regulatory proteins on peripheral blood cells of systemic lupus erythematosus patients
by: Ana Paula Alegretti, et al.
Published: (2009-06-01)

R-DOTAP Cationic Lipid Nanoparticles Outperform Squalene-Based Adjuvant Systems in Elicitation of CD4 T Cells after Recombinant Influenza Hemagglutinin Vaccination
by: Thomas R. Henson, et al.
Published: (2023-02-01)

Promising Adjuvants and Platforms for Influenza Vaccine Development
by: Wandi Zhu, et al.
Published: (2021-01-01)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
by: Daniela Amicizia, et al.
Published: (2023-01-01)

Adjuvant-attenuated symptom severity of influenza infections in vaccinated children
by: Charlotte Switzer, et al.
Published: (2022-09-01)

The Cytolytic Activity of Vaginolysin Strictly Depends on Cholesterol and Is Potentiated by Human CD59
by: Milda Zilnyte, et al.
Published: (2015-01-01)

Cd59 and inflammation regulate Schwann cell development
by: Ashtyn T Wiltbank, et al.
Published: (2022-06-01)

Advances in Adjuvanted Influenza Vaccines
by: Shintaro Shichinohe, et al.
Published: (2023-08-01)

Flow cytometric analysis of erythrocytes in paroxysmal nocturnal hemoglobinuria reveals superiority of CD59 as a diagnostic marker compared to CD55
by: Tembhare Prashant, et al.
Published: (2010-10-01)

Reduced Expression of Membrane Complement Regulatory Protein CD59 on Leukocytes following Lung Transplantation
by: Laura A. Michielsen, et al.
Published: (2018-01-01)

The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice
by: Kangwei Xu, et al.
Published: (2024-01-01)

VaxcineTM: an oil-based adjuvant for influenza vaccines
by: Rosely Cabette Barbosa Alves, et al.
Published: (2011-12-01)

Adjuvanted Influenza Vaccines Elicits Higher Antibody Responses against the A(H3N2) Subtype than Non-Adjuvanted Vaccines
by: Laura Sánchez de Prada, et al.
Published: (2020-11-01)

Comparative analysis of visual quality after implantation of Symfony IOL and MF15 IOL
by: Rong Guo, et al.
Published: (2022-08-01)